Wilson Sonsini Goodrich & Rosati

Wilson Sonsini Goodrich & Rosati is the premier provider of legal services to technology, life sciences, and growth enterprises worldwide and has one of the largest life sciences practices in the United States. The firm has a 60-plus-year history of representing trailblazers in the life sciences industry, from the earliest innovators to those shaping the future of healthcare today. Our multidisciplinary team of attorneys, patent agents, and scientific advisors works closely with entrepreneurs, scientists, and investors who trust the firm’s strategic advice to establish and realize their companies’ business objectives, which includes protecting and leveraging their most valuable IP assets. We represent life sciences companies through the entire business life cycle, from formation through IPO and strategic partnerships, and often act as outside general counsel with support from our cross-functional, global life sciences team. Our clients include thousands of innovation-focused life sciences companies, research institutions, start-up accelerators and incubators, and the venture capital funds and banks that finance the industry.  

www.wsgr.com

上海市生物医药科技产业促进中心

上海市生物医药科技产业促进中心（简称“市生药中心”）最早成立于1994年，是上海市科学技术委员会直属的公益二类、差额拨款的科学研究类事业单位。中心主要职能是承担本市生命科学、生物医药领域科技创新和产业发展的相关研究、共性技术研发、项目管理服务、科创基地建设、科技成果转化、招商引资和企业服务、人才培训，以及人类遗传资源管理服务、实验动物管理等职能。

www.biomed.org.cn

汉康资本

汉康资本成立于2015年，是一家专注于生物医药领域的专业风险投资机构。总部位于上海，并在北京和香港设有分支机构，我们致力于将中国的研发优势与全球创新相结合。在“赋能生物医药创新，守护人类健康”这一使命的引领下，我们与具有全球视野的创业者并肩协作，在药物研发的全生命周期提供端到端支持。我们的目标是在全球范围内推动突破性疗法的进步，以解决重大治疗领域和多样化药物形式中关键的、未被满足的临床需求。目前，汉康资本已投资50多家高潜力的企业，助力了包括康方生物、诺诚健华、康诺亚生物、和誉生物、映恩生物和维立志博在内的多家行业领先企业。我们的投资组合在二级市场保持了稳健的业绩记录，并与全球跨国药企达成了广泛的对外授权及共同开发合作。随着数十款药物相继获得NMPA和FDA的监管批准，汉康资本将继续致力于创造持久的临床价值和投资影响力。

RA Capital Management

Ascentage Pharma

JP Morgan

METiS TechBio

Tigermed